1. Efficacy and Safety of Dabigatran vs. Warfarin in Patients with Atrial Fibrillation - Japanese population in the RE-LY ® - Shinya Goto, MD., PhD. Tokai University School of Medicine C. Michael Gibson, M.S., M.D. Beth Israel Deaconess Medical Center, Harvard Medical School, Duke Clinical Research Institute

2. Dabigatran etexilate has been shown to concurrently reduce both thrombotic and haemorrhagic events Both doses of dabigatran provide different and complementary advantages over warfarin –150 mg BID showed 35% statistically significant reduction in stroke/systemic embolism with similar bleeding –110 mg BID showed comparable rates of stroke/systemic embolism has significantly less bleedings with similar efficacy RE-LY ® - Overall Summary

3. RE-LY ® - Baseline Characteristics in Japanese Population CharacteristicOverallJapan Randomized18,113326 Mean age (years)71.571.2 Male (%)63.676.7 CHADS 2 score (mean) 0-1 (%) 2 (%) 3+ (%) 2.1 31.9 35.6 32.5 2.2 31.3 34.0 34.7 Prior stroke / SEE / TIA(%)21.833.1 Prior MI (%)16.65.5 CHF (%)32.031.0 Baseline ASA (%)39.835.9 VKA naive (%)50.456.1 Hori M, et al: Circ J 2011; 75: 800 - 805, 2011

4. RE-LY ® - Stroke or Systemic Embolism OverallJapan % per year 150mg bid 110mg bid (n=134/6,076) (n=183/6,015) (n=202/6,022) % per year 150mg bid 110mg bid (n=1/111) (n=12/107) (n=4/108) RR 0.90 (95% CI: 0.74-1.10) RR 0.65 (95% CI: 0.52-0.81) RR 0.52 RR 0.25 Connolly SJ, et al.: N Engl J Med 363, 1875-1876, 2010 Hori M, et al: Circ J 2011; 75: 800 - 805, 2011

5. RE-LY ® - Plasma Concentration of Dabigatran in Overall and Japanese Overall Japanese Cpre,ss: Pre dose plasma concentrations at steady state C2,ss : Plasma concentration at 2 hours after drug administration at steady state (approximate maximum plasma concentration) Hori M, et al: Circ J 2011; 75: 800 - 805, 2011

6. Country Distribution of Mean Time in Therapeutic Range (TTR) in the RE-LY® Wallentin L, et al.: Lancet, 376: 975-83, 2010

7. RE-LY ® - INR Control / TTR RegionNINR <2INR 2-3INR>3 Overall5,78922.2%64.4%13.5% Japan10836.8%57.6%5.6% JCS guideline for pharmacotherapy of atrial fibrillation 2008: 2.0~3.0 for <70 years 1.6~2.6 for ≧ 70 years RE-LY in Japanese subgroup adapts INR 2.0-3.0 for <70 years and INR 2.0-2.6 for ≧ 70 years

8. The result of Japanese subgroup is basically consistent with overall results of RE-LY ®. The demographics of the Japanese subgroup differ from the overall population in prior stroke and MI of RE-LY but the overall risk score is similar. PK profile between Japanese subgroup and overall is similar. Based on the Japanese guideline criteria, the INR control of warfarin was well- controlled. RE-LY ® - Conclusions